Situation: A 40-year-old man with bipolar I disorder has taken lithium carbonate 450 mg orally twice daily for 2 years. His trough serum lithium levels have been 0.8–0.9 mEq/L (therapeutic range 0.6–1.2 mEq/L; toxic above 1.5 mEq/L). He is followed at an outpatient mental health clinic. Over the next year, different prescribers write each of the following for his hypertension. Which one can the nurse give without first raising a concern about his lithium therapy?

Thiazide diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and nonsteroidal anti-inflammatory drugs reduce renal lithium clearance and raise serum levels, so each needs clarification or closer level monitoring. Amlodipine is not in this group.

Why amlodipine is the safe choice

Lithium is excreted almost entirely by the kidneys, and its clearance depends heavily on renal blood flow, glomerular filtration, and proximal tubular sodium handling. Any drug that reduces effective circulating volume, lowers glomerular perfusion, or promotes proximal sodium reabsorption will decrease lithium excretion and raise the serum level. This is the central mechanism behind most clinically important lithium drug interactions ^[1].

Amlodipine, a dihydropyridine calcium channel blocker, lowers blood pressure through arteriolar vasodilation without reducing renal perfusion pressure in a way that impairs lithium clearance. It does not act on the renin–angiotensin–aldosterone system, does not alter proximal tubular sodium reabsorption, and does not produce volume contraction. Therefore, it does not belong to the group of antihypertensives that predictably raise serum lithium concentrations ^[1][2].

The three options that do require concern

The other three choices all reduce renal lithium clearance through distinct but converging pathways.

Drug class	Example	Mechanism of lithium interaction	Clinical consequence
Thiazide diuretic	Hydrochlorothiazide	Volume contraction and increased proximal tubular sodium and lithium reabsorption	Marked rise in serum lithium; risk of toxicity even at previously stable doses
ACE inhibitor	Enalapril	Reduced angiotensin II lowers glomerular efferent arteriolar tone, decreasing GFR and lithium filtration	Reduced lithium clearance; serum level rises
Angiotensin receptor blocker	Losartan	Same hemodynamic effect on efferent arteriole and GFR as ACE inhibitors	Reduced lithium clearance; serum level rises

Thiazide diuretics are the most notorious in this group. By causing sodium depletion, they trigger compensatory proximal tubular sodium reabsorption, and because lithium is handled similarly to sodium in the proximal tubule, lithium reabsorption increases in parallel. The result can be a substantial elevation in serum lithium even when the lithium dose has been stable for years ^[1][3].

ACE inhibitors and angiotensin receptor blockers act through a different route. Angiotensin II normally constricts the efferent glomerular arteriole, maintaining glomerular filtration pressure. When this effect is blocked, efferent arteriolar tone falls, glomerular filtration rate decreases, and less lithium is filtered. The net effect is reduced lithium clearance and a higher serum concentration ^[1][2].

Watch out! The patient’s trough lithium has been 0.8–0.9 mEq/L, which is within the therapeutic range of 0.6–1.2 mEq/L. Toxic effects generally appear above 1.5 mEq/L. Even a modest reduction in lithium clearance can push a previously stable patient into the toxic range, so any newly added drug from these three classes requires prescriber clarification and closer serum lithium monitoring.

Clinical reasoning for the nurse

When a new antihypertensive is ordered for a patient on chronic lithium, the nurse should first ask whether the drug alters renal hemodynamics, sodium balance, or prostaglandin-dependent renal blood flow. Amlodipine does none of these. It can be administered without first raising a concern about lithium therapy ^[1][2].

The interaction risk is not about the antihypertensive effect itself, but about whether the drug reduces lithium clearance. Calcium channel blockers of the dihydropyridine class lower blood pressure through peripheral vasodilation while generally preserving renal blood flow and glomerular filtration, which is why they are the preferred initial option when a patient on lithium needs antihypertensive treatment ^[2].

Key point! Thiazides, ACE inhibitors, and ARBs all reduce renal lithium clearance and raise serum levels. Amlodipine does not share this mechanism and is the only option that can be given without first questioning the lithium interaction.